Lista de obras - Michael S Seaman - Dominio Público Uruguay

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo

artículo científico publicado en 2015

A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1

artículo científico publicado en 2014

A method for identification of HIV gp140 binding memory B cells in human blood

artículo científico publicado en 2008

A mouse model for HIV-1 entry

artículo científico publicado en 2012

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection

artículo científico publicado en 2018

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

artículo científico publicado en 2015

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

artículo científico publicado en 2011

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

artículo científico publicado en 2010

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

artículo científico publicado en 2017

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

artículo científico publicado en 2014

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.

artículo científico publicado en 2017

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

scientific article published on June 2016

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

artículo científico publicado en 2017

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope

artículo científico publicado en 2019

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

artículo científico publicado en 2009

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

artículo científico publicado en 2012

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

artículo científico publicado en 2014

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

artículo científico publicado en 2014

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

artículo científico publicado en 2017

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

artículo científico publicado en 2003

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

artículo científico publicado en 2017

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

scientific article published in Nature

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

artículo científico publicado en 2015

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

artículo científico publicado en 2012

Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments".

artículo científico publicado en 2017

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

scientific article published on 15 October 2019

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

artículo científico publicado en 2017

Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37–45]

article

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

artículo científico publicado en 2016

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

scientific article published on 01 July 2019

Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus

scientific article published on 29 July 2009

Early antibody therapy can induce long-lasting immunity to SHIV

artículo científico publicado en 2017

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

artículo científico publicado en 2014

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

artículo científico publicado en 2012

Expansion after epitope peptide exposure in vitro predicts cytotoxic T lymphocyte epitope dominance hierarchy in lymphocytes of vaccinated mamu-a*01+ rhesus monkeys

scientific article published on 01 May 2006

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

artículo científico publicado en 2016

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site

artículo científico publicado en 2018

First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

artículo científico publicado en 2018

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

artículo científico publicado en 2010

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

artículo científico publicado en 2013

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

article

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

scientific article published on 01 August 2019

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

artículo científico publicado en 2015

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

artículo científico publicado en 2016

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

artículo científico publicado en 2012

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

artículo científico publicado en 2013

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

artículo científico publicado en 2016

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells

scientific article published on 11 April 2019

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

artículo científico publicado en 2017

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

artículo científico publicado en 2015

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

artículo científico publicado en 2004

Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies

artículo científico publicado en 2020

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

artículo científico publicado en 2016

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models

artículo científico publicado en 2013

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

artículo científico publicado en 2015

Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.

scientific article published on 23 January 2009

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

artículo científico publicado en 2014

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

artículo científico publicado en 2015

Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers

artículo científico publicado en 2016

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

artículo científico publicado en 2011

Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques

artículo científico publicado en 2024

Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes

artículo científico publicado en 2014

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

artículo científico publicado en 2011

Intra-spike crosslinking overcomes antibody evasion by HIV-1

artículo científico publicado en 2015

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants

artículo científico publicado en 2012

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

artículo científico publicado en 2016

Neutralization tiers of HIV-1.

artículo científico publicado en 2017

Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.

artículo científico publicado en 2018

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo

artículo científico publicado en 2017

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

artículo científico publicado en 2016

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

artículo científico publicado en 2012

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

artículo científico publicado en 2016

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments

artículo científico publicado en 2017

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

artículo científico publicado en 2010

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma

artículo científico publicado en 2017

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

artículo científico publicado en 2016

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

artículo científico publicado en 2018

Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir

artículo científico publicado en 2019

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

artículo científico publicado en 2017

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys

artículo científico publicado en 2006

Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

artículo científico publicado en 2014

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

article

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences

artículo científico publicado en 2016

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

artículo científico publicado en 2008

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

artículo científico publicado en 2017

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys ⬇️

scientific article published on 24 October 2013

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

artículo científico publicado en 2010

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

artículo científico publicado en 2014

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

artículo científico publicado en 2004

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

article

Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC

article

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

artículo científico publicado en 2005

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

artículo científico publicado en 2013

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

artículo científico publicado en 2020

Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys

artículo científico publicado en 2010

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

artículo científico publicado en 2011

Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env

artículo científico publicado en 2021

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

artículo científico publicado en 2013

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates

artículo científico publicado en 2021

Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo

artículo científico publicado en 2004

TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

artículo científico publicado en 2018

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

artículo científico publicado en 2013

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

artículo científico publicado en 2009

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

artículo científico publicado en 2012

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

artículo científico publicado en 2015

Lista de obras de Michael S Seaman

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo

A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1

A method for identification of HIV gp140 binding memory B cells in human blood

A mouse model for HIV-1 entry

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments".

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37–45]

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus

Early antibody therapy can induce long-lasting immunity to SHIV

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

Expansion after epitope peptide exposure in vitro predicts cytotoxic T lymphocyte epitope dominance hierarchy in lymphocytes of vaccinated mamu-a*01+ rhesus monkeys

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site

First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques

Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Intra-spike crosslinking overcomes antibody evasion by HIV-1

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

Neutralization tiers of HIV-1.

Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials